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ince the serendipitous discoveries of chlorpro-
mazine and imipramine, the precursors of current
antipsychotics and antidepressants, respectively, we have
made arguably few strides towards the improvement of
clinical outcomes. Our major gains have been in the area
of pharmacotherapy acceptance and tolerability. The
development of serotonin reuptake inhibitors has dra-
matically reduced the side effects and lethality in over-
dose of commonly prescribed antidepressants. Similarly,
second-generation antipsychotics have significantly
decreased the incidence of extrapyramidal symptoms
(EPS), including tardive dyskinesia and parkinsonism,
but at the same time have increased the long-term like-
lihood of mortality and morbidity secondary to adverse
metabolic effects.
We remain in an era of uncertainty with regard to the
underpinnings of individual variability in order to pre-
emptively differentiate treatment responders from non-
responders. Our current evidence-based medicine relies
on large randomized control trials and meta-analyses—
average medicine, which ignores individual differences.
This dependence on large group analyses places us at a
risk of discarding subgroup-specific treatment options
owing to their failure to prove efficacious across entire
populations.1
There is a new era emerging in psychiatry of personalized
medicine that will focus on individual differences not evi-
dent phenomenologically. Much research is directed
towards the identification of genes, endophenotypes, and
363
S t a t e  o f  t h e  a r t
Copyright © 2009 LLS SAS.  All rights reserved www.dialogues-cns.org
The intersection of pharmacology, imaging,
and genetics in the development of 
personalized medicine
Philip Gerretsen, MD, MSW; Daniel J. Müller, MD; Arun Tiwari, PhD;
David Mamo, MD, MSc; Bruce G. Pollock, MD, PhD
S
Keywords: personalized medicine; pharmacogenetics; neuroimaging; antipsychotic;
antidepressant; treatment response; adverse effect; depression; schizophrenia
Author affiliations: Multimodal Imaging Group, (Philip Gerretsen); Multimodal
Imaging Group, Division of Geriatric Psychiatry (David Mamo), Centre for
Addiction and Mental Health, University of Toronto, Canada; Pharmacogenetics
Research Clinic, Neurogenetics Section (Daniel J. Müller); Neurogenetics Section
(Arun Tiwari), Centre for Addiction and Mental Health, University of Toronto,
Canada; Division of Geriatric Psychiatry, Centre for Addiction and Mental Health,
University of Toronto, Canada (Bruce G. Pollock)
Address for correspondence: Bruce G. Pollock, MD, PhD, FRCPC, Vice President,
Centre for Addiction and Mental Health Research, Sandra A. Rotman Chair in
Neuropsychiatry, Rotman Research Institute, Professor and Head Division of
Geriatric Psychiatry, University of Toronto, Faculty of Medicine, 33 Russell Street,
Room T-109, Toronto, Ontario, Canada, M5S 2S1
(e-mail: bruce_pollock@camh.net)
We currently rely on large randomized controlled trials
and meta-analyses to make clinical decisions; this places
us at a risk of discarding subgroup or individually specific
treatment options owing to their failure to prove effi-
cacious across entire populations. There is a new era
emerging in personalized medicine that will focus on
individual differences that are not evident phenomeno-
logically. Much research is directed towards identifying
genes, endophenotypes, and biomarkers of disease that
will facilitate diagnosis and predict treatment outcome.
We are at the threshold of being able to predict treat-
ment response, primarily through genetics and neu-
roimaging. In this review we discuss the most promising
markers of treatment response and adverse effects
emerging from the areas of pharmacogenetics and neu-
roimaging in depression and schizophrenia. 
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biomarkers of disease that will facilitate diagnosis and
predict treatment outcome. Pharmacogenetic studies that
explore the role of an individual’s genetic makeup in
determining the effectiveness of pharmacotherapy are of
increasing interest. The rationale for the hypothesized
role of pharmacogenetics is based on observations made
in family and twin studies, where closely related relatives
tend to show similar response or side-effect patterns
(reviewed in ref 2). All proteins, including those involved
in the metabolism and central effects of pharmaceuticals,
can differ as a result of naturally occurring variability in
the DNA sequence of the associated gene. This has led
investigators to study gene variants for their association
with antipsychotic drug outcome. Gene variants (ie, alle-
les or polymorphisms) that code for the enzymes respon-
sible for drug metabolism can affect pharmacokinetics,
and therefore the amount of drug available in the body
to elicit a response. In addition, gene variants can affect
pharmacodynamics, the therapeutic effect of a drug in the
target organ (Figure 1, “PK and PD”). Representative
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Selected abbreviations and acronyms
5-HT serotonin
5-HTTLPR serotonin transporter-linked polymorphic
region
ACC Anterior cingulate cortex
BDNF brain-derived neurotrophic factor
CYP cytochrome P450
PM poor drug metabolizer
UM ultrarapid drug metabolizer
Figure 1. The influence of pharmacokinetic, pharmacodynamic and environmental factors on pharmacotherapy response and side effects (source:
www.silvermedia.ca).
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examples in breast cancer research include the overex-
pression of the HER2 gene, a positive predictor of
response to the drug trastuzumab (Herceptin), and the
predictive value of active cytochrome P450 (CYP) 2D6
alleles in tamoxifen discontinuation.3
In psychiatry, we lack basic laboratory investigations to
diagnose mental illness, let alone genetic advances to
guide treatment. A primary goal of current research is
to characterize the etiologies and biological susceptibil-
ities of heterogeneous, complex conditions, such as
depression and psychosis. We are at the threshold of
being able to predict treatment response, primarily
through genetics and neuroimaging. 
Personalized medicine in psychiatry is a broad topic. As
such, we will confine our review to the most promising
markers of treatment response and adverse effects
emerging from the areas of pharmacogenetics and neu-
roimaging in depression and schizophrenia.
Genetics of antipsychotic drug metabolism,
response, and side effects in schizophrenia
Antipsychotic drugs remain the cornerstone of treat-
ment in schizophrenia. However, more than 20% of
patients do not initially respond to treatment with drug
therapy.4 In addition to lack of response, many patients
discontinue their medication due to side effects, which
can have serious and devastating consequences.5
In the following sections we discuss the genetics of
antipsychotic drug metabolism, response, and side effects
in schizophrenia.
Genetics of antipsychotic drug metabolism
The vast majority of antipsychotic drugs are metabolized
by the liver enzymes CYP2D6 and CYP2C19, which
play critical roles in determining plasma drug levels.
Gene variants that confer altered enzymatic activity
influence plasma drug levels, and therefore can predict
effective drug doses and potential side effects.
The CYP2D6 gene codes for an enzyme that is respon-
sible for metabolizing the majority of antipsychotic med-
ications.6 This enzyme shows genetic variability in activ-
ity and is highly polymorphic, with over 70 single
nucleotide polymorphisms (SNPs) and copy number
variations (CNVs).7 These variations can influence
antipsychotic drug activity and a patient’s ability to
metabolize them. Individuals can be classified, based on
their gene polymorphisms, as poor (PM), intermediate
(IM), extensive/normal (EM), or ultrarapid drug metab-
olizers (UM).8 The frequency of PMs, IMs, EMs, and
UMs varies across ethnicities. For example, Europeans
show the highest frequency of CYP2D6 PMs and
African-Americans show the highest frequency of
CYP2D6 UMs.9
In theory, the risk of side effects may be higher in indi-
viduals with compromised drug metabolism capabilities
because of higher drug plasma levels.10 Alternatively,
drug plasma levels may be lower and medications, as a
result, less efficacious in individuals with high enzymatic
activity.11 The vast majority of individuals will have no or
little impaired enzyme activity (ie, are IM or EM).
However, it may be extremely valuable for those indi-
viduals who show impaired (PM) or markedly increased
activity (UM) to have this information taken into con-
sideration when selecting antipsychotic medication,
determining appropriate dosage, or interpreting plasma
levels in the context of drug monitoring. 
Estimated dose adjustments for antipsychotics have
been described based on an individual’s metabolizer
status.12 CYP2D6 and CYP2C19 diagnostic testing is
FDA approved with the Roche AmpliChip®, but is
also available at decreasing costs every year through
other companies. Importantly, results from genotyping
analyses are only one factor affecting drug plasma lev-
els and should be considered in conjunction with other
important criteria, such as comedication, smoking, and
diet.6
Genetics of antipsychotic treatment response
Another important focus of investigation has been
antipsychotic drug response in schizophrenia. The first-
generation studies exploring the genetics of antipsy-
chotic treatment outcome were published in the early to
mid 1990s. They were performed with small sample sizes
and included patients treated mainly with clozapine, but
not exclusively. The most interesting findings, albeit
mixed, were obtained for the serotonin 2A (5-HT2A)
and the dopamine 2 (DRD2) receptor gene polymor-
phisms.13 These results suggested that the effect size of
these polymorphisms is low and that other factors,
including other genes and gene variants, are likely to be
involved. 
Second-generation studies have included larger samples,
more sophisticated analyses, and multiple polymor-
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phisms, which allow for the investigation of haplotypes
and genome-wide associations. These continue to pro-
duce promising results for the 5-HT2A and DRD2 gene
polymorphisms. A comprehensive analysis which
included 12 DRD2 gene polymorphisms in a sample of
232 well-characterized subjects identified protective hap-
lotypes in both Europeans and African-Americans.14 A
review by Arranz et al concluded that the –141C/T poly-
morphism in the DRD2 gene is of particular significance
due to its association with treatment outcome in two
independent samples.2 A more recent meta-analysis of
almost 700 individuals supported the association
between the –141C/T polymorphism and antipsychotic
drug response.15 Intriguingly, this polymorphism is
located in the promoter region and could have regula-
tory effects in addition to functional relevance. Although
the role of the DRD2 gene in antipsychotic response is
not conclusive, these findings are of particular interest
since D2 is the main target of antipsychotics.16
5-HT2A is proposed to be involved in the unique ther-
apeutic action of clozapine.17 Two studies with sufficient
statistical power have demonstrated a role for the struc-
tural 5-HT2A His452Tyr polymorphism in predicting
clozapine response.18,19 Significant associations have also
been described in at least a dozen other genes, such as
DRD3, DRD4, 5-HT1A, 5-HT2C, 5-HT6, 5-HTT, BDNF,
COMT, GNB3, MDR1, MTHFR, NEF3, NRG1, RGS4
and TNF-alpha.2,20,21
Of note, the first whole genome-wide association study
of antipsychotic drug response was recently conducted
by Sullivan et al.21 This approach involves no a priori
hypotheses of candidate genes or gene variants, and as a
result makes it difficult to interpret the significance of
results in the context of adequately controlling for mul-
tiple variable testing. No significant findings have been
reported thus far. 
Also of note, only a few studies have tested for a direct
association between CYP450 gene polymorphisms and
drug response. These have yielded mostly negative
results.2,22
Overall, some interesting findings exist in the area of
genetics and antipsychotic response. However, many
associations are not conclusive and represent a small
fraction of the total variance of treatment outcome.
Because the entire genome and candidate gene variabil-
ity have not been fully explored, more robust observa-
tions are expected with the utilization of DNA sequenc-
ing techniques. The category “treatment response” may
be too broad an outcome measure in genetic studies of
heterogeneous conditions. Studies that target specific
symptoms, such as neurocognitive and verbal memory
scores, may yield more convincing findings.21,23
Genetics of antipsychotic-induced side effects
Antipsychotics can induce a variety of side effects, such
as involuntary movements (eg, tardive dyskinesia) and
weight gain, both of which appear to be genetically
determined.24,25 Compared with phenotypes like treat-
ment response, an analysis of genetic factors associated
with side effects may offer several advantages. First, side
effects are often more closely related to plasma levels,
which can sometimes be predicted by gene variants
involved in drug metabolism. Second, compared with
treatment response the occurrence of side effects may
be more closely related to specific pharmacodynamic
relevant receptors. Third, some side effects such as
weight gain can be assessed more easily and reliably as
compared with complex phenotypes, such as treatment
response. 
In a prototypical study of its time, Pollock et al26 prospec-
tively distinguished poor P450 2D6 metabolizers from
EM among a group of elderly patients suffering from
dementia treated with perphenazine. The poor metab-
olizers had significantly greater side effects than the 40
extensive metabolizers.
In the case of tardive dyskinesia, previous reports have
indicated that CYP1A2 may be of importance.27 Other
studies which focused on the Ser9Gly variant of the
DRD3 gene reported significant associations, which
were supported in two meta-analyses.28,29
Several interesting studies have now been published
regarding the genetics of antipsychotic-induced weight
gain. The CYP2D6 gene has been associated with
increasing weight. In pharmacodynamic analyses, the
most consistent findings involve the promoter polymor-
phisms of the 5-HT2C gene and the leptin gene. Both
genes are involved in energy and fat metabolism in stud-
ies of humans and animals (reviewed in ref 30, Figure 2).
Further interesting findings are reported in the
ADRA2A and SNAP-25 genes, with replications in
independent samples.31-35
In summary, studies assessing the genetic underpinnings
of side effects to antipsychotic medications have yielded
interesting findings, although effect sizes for single genes
(or gene variants) are small. 
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Genetics of antidepressant response 
and drug metabolism in depression
Major depressive disorder (MDD) is one of the fourth
major causes of disability worldwide, with tremendous
socioeconomic consequences36 Adverse early life events
are major predictors of later development of MDD,
though genetic factors also appear to have a significant
influence (37% heritability in twin studies). Antidepres-
sants are the cornerstone in treating depression; how-
ever, only 50% to 70% of the patients respond to initial
therapy, and less than 40% patients achieve full remis-
sion.37 Furthermore, efficacy of an antidepressant is often
only apparent after treating for 4 to 8 weeks. A reliable
tool to predict antidepressant response would be of
great service to the clinician, leading to greater efficacy
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Figure 2. The interaction between peripheral molecules and central pathways modulating food/energy intake. AgRP, Agouti related protein, GABA,
gamma aminobutyric acid, MC4, melanocortin receptor 4, NPY, neuropeptide, POMC, proopiomelanocortin, α-MSH, alpha melanocyte stim-
ulating hormone. (source: www.silvermedia.ca)
Adapted from ref 30: Muller DJ, Kennedy JL. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics. 2006;7:863-887.
Copyright © Future Medicine Ltd, 2006.
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and rapidity of response. Pharmacogenetics offers an
individually tailored alternative to the trial and error
prescription regime. Concordance for antidepressant
response has been observed in family studies implicat-
ing the role of genetic factors.38,39
Genetics of antidepressant drug metabolism 
The therapeutic level achieved by antidepressants is
heavily influenced by the metabolic activity of the
CYP450 enzymes. CYP2D6 is involved in the metabo-
lism of most tricyclic antidepressants (TCAs) and some
SSRIs. Functional polymorphisms lead to varying
degrees of metabolic activity that influence plasma drug
levels, and allow for the categorization of distinct phe-
notypes (see Genetics of antipsychotic drug metabolism
section above).6,40,41 The UM phenotype is associated with
increased clearance of antidepressants and lack of
response.42-44 Accordingly, the PM phenotype is reported
to lead to increased adverse events with antidepressant
treatment.45,46
Some evidence suggests that functional polymorphisms
in the CYP2C19 gene also influence serum levels of 
antidepressants metabolized by this enzyme. UM
(CYP2C19*17/*17) exhibited the lowest concentrations
of escitalopram, whereas patients with the PM genotype
(CYP2C19*2 or *3) exhibited the highest serum levels.47
Genetics of antidepressant treatment response
The selection of candidate genes for investigation is
based on the hypothesized association with pharmaco-
logical targets of antidepressants. The ability of earlier
antidepressants to increase the availability of
monoamines within the synapse by either blocking
monoamine reuptake (eg, imipramine) or inhibiting
monoamine oxidase (eg, iproniazid) led to the
monoamine-deficiency hypothesis of depression. As a
result, several genes from the monoaminergic systems
(eg, serotonin, noradrenaline, and dopamine receptors
and transporters) have been investigated for their asso-
ciation with response to antidepressant treatment.48
Among these, the serotonergic system is the most
widely investigated. Genetic variation within the sero-
tonin transporter (5-Hydroxytryptamin transporter, 5-
HTT; SLC6A4) is suspected of conferring a vulnerabil-
ity to anxiety and affective disorders. 5-HTT is the
principal site of initial action for several antidepressants,
including selective serotonin reuptake inhibitors
(SSRIs).49 Polymorphisms within the promoter region
were described shortly after the original isolation of the
SLC6A4 cDNA on chromosome 17q12 by Lesch et al.50
In particular, a site approximately1200 bp 5’ of the first
exon of the SLC6A4 gene involves a 22 bp repetitive
sequence consisting of two subtypes, a short (S) allele
with 14 copies and a long (L) allele with 16 copies.51 This
variation is frequently referred to as the serotonin trans-
porter-linked polymorphic region (5-HTTLPR). The S
allele is associated with a reduction of function as com-
pared with the L allele. Cells homozygous for the L
variant can have up to 66% more 5-HTT mRNA
expression, greater serotonin transporter density in
platelet and neuron cell membranes, and two times the
serotonin uptake than cells with the S/S genotype
(Figure 3). 52-57
The L variant is generally associated with a better anti-
depressant response in Caucasian patients.58 In a meta-
analysis by Serretti et al, L carriers had better response
and remission rates within 4 weeks of antidepressant
treatment when compared with subjects with the SS
genotype. Conversely, in an investigation of the
STAR*D sample treated with citalopram (total n=1659)
no association was observed between the 5-HTTLPR
polymorphism and treatment tolerance or outcome.59 In
another analysis of the STAR*D sample a significant
association was found between the L allele and remis-
sion in white nonhispanic patients.60
Recently, the Genome Based Therapeutic Drugs for
Depression (GENDEP) study61 found that the L allele
was associated with better response to escitalopram. A
significant interaction was identified between 5-
HTTLPR, drug and gender, with the effect concen-
trated in males. Of note, the single nucleotide polymor-
phism (SNP) rs2020933, found at the 5’ end of the
5-HTTLPR gene, also influenced treatment outcome in
this study.
A common A>G functional polymorphism within the L
allele has also been identified.51 The G variant of this
polymorphism (LG) shows transcription levels similar
to the S allele, whereas the A genotype (LA) shows
higher expression levels. In the STAR*D study they
reported a significant association between the LA allele
and reduced adverse events in the white nonhispanic
population, but not with treatment outcome.59
The influence of 5-HTTLPR on antidepressant response
is quite robust to ethnic differences although significant
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heterogeneity exists in Asian samples.62 In contrast to
Caucasian subjects, Asians carrying the S allele have
been reported to respond better to antidepressants,
although findings are mixed (see refs 37, 58, 63). 
Another gene of active investigation is HT2RA, which
codes for the 5-HT2A receptor, a target of both antide-
pressant medications and second-generation antipsy-
chotics. A polymorphism rs7997012 found in the second
intron was significantly associated with citalopram
response in the STAR*D study.64 In addition to this vari-
ant, the A1438G polymorphism also showed evidence of
association with treatment outcome. Participants who
were homozygous for the A allele had an 18% absolute
risk reduction of having no treatment response compared
with those homozygous for the G allele. This finding
appeared specific to white subjects. Conversely, the
GENDEP study61 failed to replicate this association with
rs7997012, and found that the G allele of another poly-
morphism, rs9316233, was associated with escitalopram
response. Inconsistent findings have also been reported
for the C allele of the T102C polymorphism.58 Despite the
lack of consistent findings for a specific polymorphism
moderating response, the HT2RA gene as a whole
appears to be of importance in depression outcome.
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Figure 3. Serotonin transporter gene (SLC6A4) and function. 5-HTTLPR x PFC/Amygdala endophenotype interaction. Allelic variation of the serotonin
transporter (5-HTT), including the serotonin-transporter-gene-linked polymorphic region (5-HTTLPR), the variable number of tandem repeats
(Intron 2 VNTR), rs25531 single nucleotide polymorphism (SNP), and the missense variant lle425Val (l425V). The long (L) allele (orange) of
5-HTTLPR produces significantly less 5-HTT mRNA and protein expression, than the short (S) allele (blue), leading to higher concentrations
of serotonin in the synaptic cleft. 5-HTTLPR s allele carriers show significantly less functional coupling between the amygdala and perigen-
ual anterior cingulate cortex than L/L individuals. MAOA, monoamine oxidase A. (source: www.silvermedia.ca)
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Many other genes associated with the different
monoaminergic systems that are either inconsistently
associated with antidepressant response or that have
produced contradictory results are reviewed in detail
elsewhere (see refs 58, 63). These include HTR1A,
TPH1, TPH2, MAOA, MAOB, COMT, DAT1, SLC6A3,
D2, D3, D4, NET1, SLC6A2, ADRA2A, ADRB1, G pro-
tein, beta polypeptide 3.
Brain-derived neurotrophic factor (BDNF) is an impor-
tant peptide abundantly expressed in limbic structures.
BDNF is critical for axonal growth, neuronal survival,
and synaptic plasticity. The observations of stress-induced
decrease in hippocampal BDNF levels and increase in
BDNF-mediated signaling following chronic treatment
with antidepressants suggest a possible role in depression
and its treatment.48,65,66 However, inconsistent and region-
specific effects have also been observed.48 A functional
coding SNP rs6265 causes a Valine to Methionine change
at codon 66, which leads to impaired intracellular traf-
ficking and secretion of the mature BDNF protein.
Carriers of the Met allele have significantly lower hip-
pocampal volume than subjects homozygous for the Val
allele.67 Although several studies have found an associa-
tion between the Met allele and antidepressant
response,63,68 the sample sizes were small, and the results
have been inconsistent.61 In addition to the Val66Met
allele, a polymorphism in the 5’ untranslated region of
the BDNF gene (rs61888800) was associated with anti-
depressant response in Mexican-American subjects.69
This observation requires replication.
Early life stress and dysregulation of the hypothalamic-
pituitary-adrenal (HPA) axis are also linked with depres-
sion treatment outcome.48,70 One of the important genes
that has emerged from the HPA axis is FKBP5 (FK506
binding protein 51), a cochaperone of 90 kDa heat shock
protein, which regulates glucocorticoid receptor sensi-
tivity. Carriers of the TT genotype of rs1360780 poly-
morphism in intron 2 of FKBP5 were demonstrated to
have a better treatment outcome than other genotypes.71
This observation was replicated in a separate sample in
the same study, and in two other independent studies.
Smaller investigations of Spanish and Korean popula-
tions failed to reproduce this association (see ref 72). 
Genetics of antidepressant-induced side effects
Side effects of antidepressant treatment have emerged as
important reasons for medication discontinuation and non-
compliance. The first-generation TCAs and monoamine
oxidase inhibitors (MAOIs) were primarily associated with
sedation, weight gain, and anticholinergic side effects,
including dry mouth, blurred vision, cardiac effects, and
death by overdose. The newer antidepressants, including
SSRIs and SNRIs, have better and safer side-effect profiles,
but tend to cause nausea, diarrhea, nervousness, agitation,
insomnia, and sexual side effects. 
Similar to studies of antidepressant response, the candi-
date genes extensively investigated in relation to anti-
depressant induced side effects are from the serotoner-
gic system. The presence of the 5-HTTLPR L allele is
generally associated with fewer treatment related side
effects. Negative studies are also reported in the litera-
ture. A recent meta-analysis found the L allele conferred
protection against antidepressant side effects for all anti-
depressants (OR 0.64),63 the significance of which
became more robust when analyzed with SSRI-induced
side effects only. The same meta-analysis found that the
presence of the -1438 G/G polymorphism of HTR2A
increased the risk of antidepressant side effects (OR
1.91). Several other pharmacodynamic genes were inves-
tigated with contradictory results.63
Although strongly related to drug plasma levels, few
important discoveries have been made linking pharma-
cokinetic associated genes and antidepressant-induced
side effects. CYP2D6 polymorphisms are reported to
influence the emergence of TCA and MAOI side effects,
but not the majority of the newer antidepressants (for
details see ref 72). Thus, the clinical utility of pharmaco-
kinetic genes predicting side effects remains limited. To
date, the most promising observations of an association
between genes and antidepressant side effects have
come from the 5-HTTLPR polymorphism. 
Personalized medicine and neuroimaging
A major barrier to progress in the study of complex dis-
eases, such as schizophrenia and depression, is the het-
erogeneity arising from etiological and phenotypic diver-
sity. A significant amount of neuroimaging research has
been conducted to identify biomarkers or endopheno-
types which may reduce the heterogeneity. Proximal
markers are presumed to be less genetically complex
than the clinical phenotype. The identification of inter-
mediary phenomena and specific gene-endophenotype
linkages may increase the individual variability
explained by candidate genes. The validity of biomark-
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ers and endophenotypes is contingent on their sensitiv-
ity and specificity for the disease in question.37
In the next sections we present the most promising neu-
roimaging markers of treatment response in depression
and schizophrenia.
Neuroimaging markers of antidepressant treatment
outcome
Anterior cingulate cortex
The most commonly reported finding in neuroimaging
studies of depression is that increased rostral anterior
cingulate cortex (rACC) activity predicts later response
to depression treatment, including antidepressants,73-75
CBT,76 and sleep deprivation.77 Structural MRI mea-
surements of the ACC have also demonstrated an asso-
ciation with treatment response.78 The ACC is implicated
in numerous brain functions, likely due to its neu-
roanatomical position as a bridge between frontal corti-
cal and subcortical structures.37 The rACC, primarily
Brodmann area 25, is consistently reported to be hyper-
active in depressed treatment responders.79 According to
Mayberg et al’s theory of depression, cortical-subcorti-
cal regulation shifts from the dorsolateral to the ventro-
lateral prefrontal cortex (PFC), which contributes to
rACC hyperactivity.75 It is this region that is a target of
deep brain stimulation (DBS) studies of treatment-resis-
tant depression.80 In further support of this theory, two
independent groups of researchers have identified
increased pretreatment activity in rACC theta activity
in responders using low-resolution electromagnetic
tomography.81,82
Functional neuroimaging studies during active task con-
ditions can facilitate distinguishing responders from non-
responders by targeting the neurocircuitry involved in
depression.37 The aim is to reduce unexplained back-
ground cerebral activity (“noise”) present during the rest-
ing state, thereby increasing the signal-to-noise ratio.
Common approaches involve comparing the brain regions
activated during the presentation of affectively laden or
sad facial expressions versus neutral or positive stimuli. In
an fMRI study by Chen et al,78 participants who displayed
greater pretreatment activation within ACC in response
to negative versus neutral stimuli displayed the greatest
response to treatment.73,74,83 Other fMRI studies have also
demonstrated a relationship between pretreatment ACC
activity and treatment outcome.73,74
Amygdala
Greater pretreatment amygdala activity is also associ-
ated with treatment response. Increased signal in the
amygdala following the presentation of negative facial
expressions is related to major depression severity84,85
and was demonstrated to predict improvement.86
Normalization of amygdala reactivity to affective stim-
uli is consistently reported to occur with antidepressant
treatment.74,87,88 The same study that reported an associ-
ation between PFC activity and response to CBT found
that heightened amygdala activity to negative words also
predicted response.76 Intriguingly, there is evidence to
suggest that the variability in amygdala and PFC activ-
ity is moderated, in part, by the serotonin transporter
gene 5-HTTLPR. 
5-HTTLPR x PFC/Amygdala endophenotype interaction
5-HTTLPR appears to have modulatory effect on emo-
tion89 via top-down cortico-amygdala regulation.1 On the
one hand, diminished cortical structure and function is
associated with depression and anxiety. Results from
functional brain imaging studies suggest that the S allele
contributes to increased amygdala reactivity via direct
anterior cingulate (ACC)-amygdala dysregulation,90,91
and indirect compensatory activation of the ventrome-
dial prefrontal cortex (Figure 3).91 Consistent with these
findings, the S allele was associated with peak gray-mat-
ter volume reductions in the subgenual ACC, a structure
implicated in both depression and anxiety.92 This theory
is substantiated by the dense serotonergic connections
between the ACC and amygdala in comparison with the
relatively few amygdala connections with the ventro-
medial PFC.91 On the other hand, the gain of function L
allele had the opposite effect of the S variant on cortico-
amygdala regulation.90,91 The LA/LA genotype confers a
modest risk of OCD,51 which is associated with hyper-
frontality, including increased ACC metabolic activity
and gray matter volume.93
Hippocampus
Lower hippocampal volume is associated with depres-
sion, frequency of episodes, and chronicity of illness.94
Hippocampal volume loss, as measured with structural
MRI, is also characteristic of late-life depression and
may be independently influenced by the val66met
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BDNF (See section Genetics of antidepressant drug
response) and 5-HTTLPR polymorphisms. 
5-HTTLPR appears to influence the pathogenesis of
depression depending on the age of onset.1 The S allele
was associated with reduced hippocampal volumes in
elderly subjects with early-onset depression (ie, first
episode 50 years or younger), while homozygosity for
the L variant predicted smaller hippocampal volumes in
depressed subjects with later onset.95 By contrast, the
L/L genotype appears to contribute to the relationship
between late-onset depression and dementia. Reduced
hippocampal volume in this context may represent the
effects of subcortical ischemia in vascular cognitive
impairment96 or the prodromal symptoms of depression
often seen in Alzheimer’s dementia.97
Although not consistently reported, some studies have
shown that antidepressant treatment may prevent or
even reverse hippocampal atrophy via neurogenesis.98,99
More research is required to determine the reliability of
hippocampal atrophy as a predictor treatment response.37
Other regions
White matter hyperintensities on structural MRI nega-
tively predict treatment response in late-onset depres-
sion.100,101 Fewer white matter lesions are associated with
remission and maintenance of remission in late-life
depression with antidepressant treatment.101 White mat-
ter disease commonly results in varied neuropsycholog-
ical deficits, primarily memory, executive, and language
function,102 which are associated with poor response to
antidepressants.37
Although the 5-HT transporter is widely believed to be
involved in the pathogenesis and treatment of depres-
sion, positron emission tomography (PET) studies have
shown both increased and decreased binding potential
of the 5-HT transporter in the context of depression.
These mixed results may reflect inter-study variation of
etiology or mood state leaving it as an unreliable bio-
marker at present.103
Neuroimaging markers of antipsychotic treatment 
outcome
Neuroimaging findings predicting treatment response to
antipsychotics are less robust than those for antidepres-
sants. Both brain atrophy by various measures (eg, sul-
cal width, ventricle size, etc.) and rate of gray matter loss
are associated with poorer treatment outcome.
Ventriculomegaly104 and cortical105 and cerebellar atro-
phy106 were found to predict response. More recently, the
extent of gray matter atrophy over time was a better
predictor of outcome than baseline abnormalities.107
Neurochemical (PET) imaging offers a minimally inva-
sive means of exploring distinct properties and cerebral
distribution of neurotransmitter systems in vivo through
the binding of receptor specific radiotracers. Binding
potential is a principal measure in PET imaging studies
that reflects both the density of available neuroreceptors
and the affinity of a radiotracer to a given receptor. PET
studies of dopamine 2 receptor (D2) binding potential
have shown that greater than 60% occupancy is associ-
ated with increased likelihood of antipsychotic response,
while greater than 80% robustly predicts EPS.108 The
clinical application of neurochemical PET imaging
remains limited by cost and availability, and while it has
been instrumental in the reduction of antipsychotic dos-
ing over the past decade and predicting dosing of sec-
ond-generation antipsychotic drugs, it has not been
applicable to the individual patients due to high inter-
subject variability. However, a recent line of investiga-
tion in older patients with schizophrenia has provided
new evidence from neuroreceptor PET imaging that
may have potential for bedside translation. These stud-
ies have suggested that measurable changes in receptor
reserve with aging is associated with antipsychotic med-
ication and that medicated older patients on a stable
dose of risperidone maintain individually consistent lev-
els of receptor occupancy, plasma concentration, and
psychopathology, supporting the use of this technology
in prospective studies.109 Presuming medication adher-
ence, PET imaging data may, in the future, be used to
facilitate the determination if worsening symptomatol-
ogy or side effects are either due to alterations in neu-
rochemistry or drug failure. Theoretically, this could be
performed with antidepressant radiotracers specific for
the serotonin transporter as well.110
In the future, PET imaging in conjunction with genetic
testing for CYP 450 metabolism may help define indi-
vidually tailored antipsychotic dosing schedules. UM
may require higher doses of an antipsychotic to achieve
the desired receptor occupancy, beyond the upper limits
of what is currently defined as the normal range.
Conversely, PM may require typically subtherapeutic
doses to avoid developing side effects, such as EPS.
Preliminary work directed towards age-specific dosing
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of antipsychotics has shown that EPS occurs at 50% to
70% D2 receptor occupancy in the elderly, which sug-
gests treatment efficacy occurs at even lower receptor
blockade (~40% to 50%).111 In the same study, a very
strong association was observed between D2 receptor
occupancy and antipsychotic plasma levels. Pending
replication, these results raise the possibility of predict-
ing individualized antipsychotic dosing. Using popula-
tion pharmacokinetic methodology in conjunction with
neuroreceptor PET data, our group is currently inves-
tigating the predictive validity of individualized antipsy-
chotic dosing using widely available bedside measures
including plasma drug levels, drug dose, demographic
factors, and concomitant medications.112
Conclusion
Personalized medicine promises the development of indi-
vidually designed treatments based on the integration of
all clinically relevant information, including data derived
from laboratory, genetic, and imaging investigations, etc.
The identification of pharmacogenetic and neuroimaging
biomarkers associated with side effects and treatment
response are active areas of research in psychiatry. The
question is, when will genetic testing and sophisticated
functional neuroimaging studies be implemented in clin-
ical practice? With regards to genetic testing, a relative
timeline can already be given. Genetic tests for critical
drug-metabolizing genes, such as CYP2D6 and CYP2C19,
are already available and can provide clinically useful
information, potentially improving response rates and
safety for those individuals who are poor or rapid metab-
olizers.113 It remains uncertain whether widespread geno-
typing prior to the onset of treatment therapy can con-
tribute substantially to therapeutic outcome. 
Challenges facing the field include phenotypic and etio-
logical heterogeneity, technological limitations, and con-
temporary research approaches. It seems that genetic
testing for side-effect prediction has the highest likeli-
hood of being incorporated into clinical practice.
Supporting this, a test for clozapine-induced agranulo-
cytosis is now available with satisfying sensitivity and
specificity.114 Computational models that include gene
variants and other factors associated with antipsychotic-
induced weight gain have yielded promising results.115
Tests related to treatment response may follow through
the inclusion of more sophisticated genotyping tech-
niques (eg, sequencing) and the analysis of refined
endophenotypes, such as specific symptoms or symptom
clusters. Future development of algorithm-based
approaches requires the integration of additional genetic
and nongenetic factors. 
Neuroimaging research has produced encouraging asso-
ciations between imaging endophenotypes and treat-
ment outcome, such as the 5-HTTLPR x PFC/amygdala
interaction. Nonetheless, these observations lack the pos-
itive and negative predictive value required to reliably
distinguish responders from nonresponders to be used
clinically. Based on current research, imaging markers
explain a significant, but modest, portion of the total
variance. More research is required with larger, less het-
erogeneous samples in conjunction with other markers,
eg, genotyping and electrophysiological measures. 
Most neuroscience research thus far involves the appli-
cation of various theoretical approaches (ie, neuroimag-
ing, genetics, neuropsychological, and physiological, etc)
in isolation. The next step in the development of per-
sonalized medicine is the formation of standardized mul-
timodal research models to better characterize markers
of treatment response. Now is a time for optimism in the
emerging ability of pharmacogenetics and neuroimag-
ing to provide meaningful help to the physician in devel-
oping individually tailored treatments for complex, het-
erogeneous psychiatric disorders. ❏
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La intersección de la farmacología, las 
imágenes y la genética en el desarrollo 
de la medicina personalizada
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